Business Wire

Samsung Bioepis and Biogen Announce Pooled Analysis Results of Anti-TNF Biosimilars BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab) at EULAR 2018

Share

Samsung Bioepis Co., Ltd. and Biogen (Nasdaq:BIIB) today announced pooled analysis results of three anti-tumor necrosis factor (anti-TNF) biosimilars – BENEPALI™ (SB4, etanercept biosimilar), FLIXABI™ (SB2, infliximab biosimilar), and IMRALDI™ (SB5, adalimumab biosimilar) – which will be presented at the Annual European Congress of Rheumatology (EULAR 2018) held June 13–16 in Amsterdam, Netherlands.

“Since BENEPALI and FLIXABI launched more than two years ago, they have played an increasingly important role in widening access to life-enhancing treatment options for patients and healthcare systems across Europe,” said Chul Kim, Head of Clinical Sciences Division, Samsung Bioepis. “We remain committed to advancing our strong pipeline of biosimilar candidates, so that more patients and healthcare systems across the region will be able to benefit from biosimilars.”

Data from three separate Phase III randomized, double-blind studies compared the efficacy and safety of BENEPALI in reference to etanercept (ETN); FLIXABI to infliximab (INF); and IMRALDI to adalimumab (ADL). The data were pooled and analyzed to assess the impact of anti-drug antibodies (ADAbs) on efficacy and tolerability, as well as radiographic progression by disease activity state.

Each clinical study had similar study designs and population demographics, and the same primary endpoint of ACR20 response rate. All patients included in the studies had been diagnosed with moderate to severe rheumatoid arthritis (RA) despite previous methotrexate treatment.

“This analysis presents a unique opportunity to compare the efficacy of three anti-TNFs in slowing the progression of joint erosion in patients with moderate to severe RA, as measured by radiographic progression,” said Ian Henshaw, Global Head of Biogen’s Biosimilar Unit. “We look forward to continuing to collaborate with Samsung Bioepis to provide guidance on treatment algorithms and as we work toward our goal of expanding access to biosimilars for patients who may benefit in Europe and around the world.”

Immunogenicity data from 1,710 patients with RA pooled from the three studies revealed that the incidence of ADAb was comparable between the biosimilars and their reference products – indicating that the biosimilars were equally effective as their biologic counterparts. In addition, efficacy and injection site reactions/infusion related reactions (ISR/IRR) were evaluated in relation to the presence of ADAb. Data suggested that the development of ADAb is associated with reduced clinical efficacy and increased incidence of ISR/IRR in patients with RA.

Radiographic data from 1,263 patients participating in the studies were collected and grouped based on patient’s disease activity state at the time of the primary endpoint assessment (Week 24 or Week 30). Radiographic progression was measured using the modified Total Sharp Score (mTSS) at Week 0 and Week 52 or Week 54. Overall, radiographic progression was minimal and comparable across all treatment groups. In addition, the pooled biosimilar group tended to have a lower mean change in mTSS compared with the pooled reference group, which slows down the progression of this disease.

Since the European Commission granted marketing authorization for BENEPALI and FLIXABI in 2016, the two biosimilars have treated nearly 80,000 patients across 23 countries.i In addition, Samsung Bioepis and Biogen expect to launch IMRALDI in Europe in October 2018 and, as a result, are on track to be the first in the industry to bring biosimilars referencing products for all three first-generation anti-TNF therapies to European patients and healthcare systems.

The two abstracts being presented at EULAR 2018 are as follows:

  • Abstract #THU0201 – A pooled analysis of three TNF-A inhibitor biosimilar studies in patients with rheumatoid arthritis comparing radiographic progression by disease activity states [Poster session: June 14, 2018 at 11:45]
  • Abstract #THU0184 – Impact of immunogenicity on clinical efficacy and administration related reaction in TNF inhibitors: a pooled-analysis from three biosimilar studies in patients with rheumatoid arthritis [Poster tour: June 14, 2018 at 12:10]

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that includes six late-stage candidates that cover the therapeutic areas of immunology, oncology and diabetes. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.

About Biogen

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.

We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – TwitterLinkedInFacebookYouTube.

Biogen Safe Harbor

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 about the results from the three Phase III studies of BENEPALI, FLIXABI and IMRALDI; the potential benefits, effects, safety and efficacy of BENEPALI, FLIXABI and IMRALDI; and planning and timing for commercial launch of IMRALDI; and the potential of Biogen’s commercial business and pipeline programs, including BENEPALI, FLIXABI and IMRALDI. These statements may be identified by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including the risk that unexpected concerns may arise from additional data or analysis, or regulatory authorities may require additional data or information or further studies, or may fail to approve, or refuse to approve, or may delay approval of our biosimilar drug candidates risks related to our dependence on third parties for the development and commercialization of biosimilars; risks of legal actions, regulatory scrutiny or other challenges to biosimilars; the risks of other unexpected hurdles; uncertainty of success in commercialization of IMRALDI, which may be impacted by, among other things, the level of preparedness of healthcare providers to treat patients, difficulties in obtaining or changes in the availability of reimbursement for IMRALDI, the effectiveness of sales and marketing efforts, problems with the manufacturing process for IMRALDI, the occurrence of adverse safety events, failure to obtain regulatory approvals in other jurisdictions, failure to protect intellectual property and other proprietary rights, product liability claims, and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

i Biogen data on file

Contact information

MEDIA CONTACT:
Samsung Bioepis
Mingi Hyun
+82-31-8061-1594
mingi.hyun@samsung.com
or
Biogen
David Caouette – U.S.
Silvia Dobry – E.U./International
+1 781 464 3260
public.affairs@biogen.com
publicaffairs.eu@biogen.com
or
INVESTOR CONTACT:
Biogen
Matt Calistri
+1 781-464-2442
IR@biogen.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin’s effects following an acute myocardial infarction26.5.2020 14:02:00 CESTPress release

Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic research collaboration with the Duke Clinical Research Institute (DCRI) on a new trial, EMPACT-MI (EMPAgliflozin for the prevention of Chronic heart failure and morTality after an acute Myocardial Infarction). The collaboration will investigate whether empagliflozin can improve outcomes and prevent heart failure in adults with and without diabetes who have had an acute myocardial infarction, more commonly known as a heart attack. This randomized clinical trial will be conducted, analyzed and reported in partnership with the DCRI, with Boehringer Ingelheim and Lilly providing funding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005445/en/ EMPACT-MI will include approximately 3,300 adults across at least 16 countries who have had an acute myocardial infarction. The primary endpoint of the trial is to assess the effect of empagliflozi

Smiths Medical Announces Ventilator Training Alliance App Partnership26.5.2020 14:00:00 CESTPress release

Smiths Medical announced today it has joined several of the world’s other ventilator manufacturers in the Ventilator Training Alliance (VTA) to support frontline medical providers access to a centralized repository of ventilator training. The content can be found in a mobile app managed by Allego. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005108/en/ Ventilator Training Alliance App (Photo: Business Wire) “Smiths Medical is proud to be a part of the VTA by providing training for our ventilators through the Allego app,” said Jeffrey Hohn, Vice President, Global Product and Commercial Excellence, Strategy and M&A at Smiths Medical. “Improving healthcare around the world is the foundation of our mission. During this critical time, we understand healthcare professionals need ventilator information quickly and the app enables the right care delivered to their patients, quickly.” The VTA app connects respiratory therapis

Panasonic and Olympian Katie Ledecky to Host Online STEAM Education Workshop to Inspire Next Generation of "Change Makers" Children26.5.2020 12:48:00 CESTPress release

Panasonic Center Tokyo (3-5-1 Ariake, Koto-ku, Tokyo, Japan. Referred to as "PC Tokyo"), the corporate global communications hub for Panasonic, has been conducting various communication activities as a corporate pavilion through exhibitions and offline events. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005385/en/ Online workshop on STEAM Education "The power to create the future" (Graphic: Business Wire) Due to the unprecedented circumstances around the world today, people's daily lives and values have been significantly impacted. We, at Panasonic, believe a new approach blending online and offline communication activities will be an essential element for corporate pavilions now more than ever. Based on this perspective, we have decided to host an online event called "The power to create the future", on Sunday, May 31, 2020. An event dedicated to children, who we believe have the ability to become "change makers" a

Fluence Broad Spectrum LED Lighting Selected for New High-Tech Quarantine Greenhouse in the Netherlands26.5.2020 12:00:00 CESTPress release

Fluence by OSRAM (Fluence) has been selected by Wageningen University & Research (WUR) as the lighting provider for Serre Red, the university’s new, high-tech quarantine greenhouse. Serre Red will be used for critical research on plant diseases—caused by viruses, bacteria, fungi and parasitic nematodes—including quarantine pathogens, as well as research on genetically modified organisms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005096/en/ Construction of the Serre Red research greenhouse nears completion at Wageningen campus (April 2020, photo courtesy of Unifarm – Wageningen University & Research) Built by Bosman van Zaal, Serre Red is one of the most advanced quarantine research facilities constructed to date. It features 63 compartments, ranging from 15 to 52 square meters with individual climate control, air filtering and access locks. Extensive technical equipment has been installed in a corridor sunk below

Alpega’s Freight Exchange, Teleroute, launches an API interface and a new mobile App to help their increasing number of customers work even more efficiently26.5.2020 11:23:00 CESTPress release

Teleroute, one of the leading freight exchanges in Europe, in its objective to continue responding to the needs of its growing number of customers, launched two major improvements to its current offering: an advanced API interface and a new version of its mobile application. Both are focused on closing a transport deal and finding new business partners more efficiently. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005339/en/ Teleroute, one of the leading freight exchanges in Europe launched an advanced API interface and a new version of its mobile application. (Photo: Business Wire) Today more than ever it is crucial for freight forwarders and transport companies to be able to quickly respond to the increasing demands of their clients. Teleroute’s new API interface allows companies to save a significant amount of time and avoid errors by posting their loads in the freight exchange directly from their TMS (Transport M

Samsung Elevates Data Protection for Mobile Devices with New Security Chip Solution26.5.2020 11:00:00 CESTPress release

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced a standalone turnkey security solution comprised of a Secure Element (SE) chip (S3FV9RR) and enhanced security software that offers protection for tasks such as booting, isolated storage, mobile payment and other applications. The latest security chip is Common Criteria Evaluation Assurance Level (CC EAL) 6+ certified, the highest level acquired by a mobile component. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005284/en/ Samsung's Secure Element (SE) chip, S3FV9RR (Photo: Business Wire) “In this era of mobility and contact-less interactions, we expect our connected devices, such as smartphones or tablets, to be highly secure so as to protect personal data and enable fintech activities such as mobile banking, stock trading and cryptocurrency transactions,” said Dongho Shin, senior vice president of System LSI marketi